The team at UT Austin developed the probes to identify the enzyme produced by some types of E. coli and pneumococcal bacteria that are resistant to treatment because of their ability to break down several common types of antibiotics, according to a news release.
About The Author
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at firstname.lastname@example.org.